

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



IN RE APPLICATION OF: YUHPYNG L. CHEN :

Examiner: Berch, M.

APPLICATION NO.: 08/764,110 :

Group Art Unit: 1611

FILING DATE: DECEMBER 6, 1996 :

TITLE: SUBSTITUTED HETEROCYCLIC :
DERIVATIVES

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**I HEREBY CERTIFY THAT THIS
CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE
AS FIRST CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C. 20231
ON THIS 07 DAY OF July 19 98
BY Kristina A. Kuras**

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the following references cited by the applicants, copies of which are enclosed.

Although no fee is believed necessary for this Information Disclosure Statement, if any fee is found necessary in connection with filing this Information Disclosure Statement, authorization is hereby given to charge such fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of the following references in connection with the examination of the above-identified application in accord with 37 CFR 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references:

1. United States Patent 5,028,605, Sablayrolles et al., July 2, 1991.

2. United States Patent 4,904,666, Friebe et al.,
February 27, 1990.
3. United States Patent 4,725,601, Ueda et. al.,
February 16, 1988.
4. United States Patent 5,561,134, Spada et al.,
October 1, 1996.
5. United States Patent 5,541,054, Miller et. al.,
July 30, 1996.
6. United States Patent 5,063,245, Abreu et. al.,
November 5, 1991.
7. United States Patent 4,605,642, Rivier et al.,
August 12, 1986.
8. WO 94/13677, June 23, 1994.
9. WO 94/13676, June 23, 1994.
10. WO 95/34563, December 21, 1995.
11. WO 95/33750, December 14, 1995.
12. EP 0 157 637 A2, October 9, 1985.
13. The American Heritage College Dictionary (Houghton
Mifflin Company USA; 1997), p.1105 and p.399.

14. Physicians' Desk Reference, 52ed. (Medical Economics Company, Inc., USA, 1998)pp. 472-474.
15. REVIA (naltrexone HCl), pp. 1-15, DuPont Pharma 1995 (www.dupontmerk.com).
16. Owens, M.J., and Nemeroff, C.B. , Pharm. Rev., Vol. 43, No. 4 pp. 425-473 (1991).
17. Strijbos, P.J.L.M., et al. Brain Res. 656, pp. 405-408 (1994).
18. Lyons, M.K., et al. Brain Res. 545, pp. 339-342 (1991).
19. Fackelmann, K.A., and Raloff, J., Psychological Stress Linked to Cancer, Science News, (Sept. 25, 1993) Vol. 144, p. 196.
20. Toshihiro, S. et al. The role of corticotropin-releasing factor and vasopressin in hypoglycemia-induced pro-opiomelanocortin gene expression in the rat anterior pituitary gland, Brain Res. (1992), 579(2), pp. 303-8.
21. Shuso, S. et al. Peripheral plasma corticotropin-releasing hormone (CHR) in an aged patient with fasting hypoglycemia associated with an insufficient secretion of insulin. An implication of plasma CRH in glucose metabolism, Nippon Naibunpi Gakkai Zasshi (1995), 71(5), pp. 659-72

References 1-3, 8, 9 and 12 were listed in the European Search Report in connection with European Application No.

96308092.4, applicant's European patent application which corresponds to the subject U.S. patent application. A copy of the European Search Report is attached hereto.

It is requested that the references listed above and on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

July 7, 1998

Kristina L. Konstas

Kristina L. Konstas
Attorney for Applicant(s)
Reg. No. 37,864

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-6380